James Shin

“First one, appreciate Ocastle achieving positive growth more than this quarter. Intending Ocastle's top-line growth and, you know, with the Riff in place, could we see autos becoming profitable on a company-level basis by, say, late 27?”

“Can you help us distinguish MK6837 from SACTMT? And then just going back to the TL1A question, is there a view within Merck that TL1A could stand alone in immunology?”

“Appreciate all the color on 989, but I just wanted to check in. Will 989's EHA update be mostly a check-the-box kind of update, or will there be some new wrinkles to glean?”

“Secondly, what's the latest on more EU adoption or reimbursement for Ocastle? And then Christian, given we're pretty much through 1Q26, can you shed any light on how Ocastle update has trended?”

“Appreciate the comments on CAR T being underpenetrated and the runway for CAR BD meeting. I mean, it's $5 billion or north of $5 billion bogey.”